Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection. Intercept’s CEO ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.

A dynamic equilibrium is formed in a reversible reaction when the rates of the forward and reverse reaction are equal and the amounts of the reactants and the products remains constant. In this ...

JANINE: Big crowd in tonight, Jeff. JEFF: Including Bob the superfan. Bob here has never actually seen Jess perform. JANINE: Let’s help him picture her in his head - we can use metaphors and similes.